NCT05766748 - Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

May 31, 2025

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Azeliragon

Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.

Trial Locations (6)

15212

RECRUITING

AHN Cancer Institute - Allegheny General Hospital, Pittsburgh

29605

RECRUITING

Prisma Health - Upstate, Greenville

33486

RECRUITING

Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton

75702

RECRUITING

Texas Oncology - Northeast Texas, Tyler

90048

RECRUITING

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

97401

RECRUITING

Williamette Valley Cancer Institute and Research Center, Eugene